We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+10.16%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.87B
AUM Growth
+$199M
Cap. Flow
+$85.5M
Cap. Flow %
2.97%
Top 10 Hldgs %
71.68%
Holding
83
New
11
Increased
14
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$92.5M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$61.6M
3
RCUS icon
Arcus Biosciences
RCUS
+$55.6M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$34.5M
5
ALEC icon
Alector
ALEC
+$21.1M

Top Sells

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$104M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$35.3M
3
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$28.9M
4
NRIX icon
Nurix Therapeutics
NRIX
+$26M
5
KYMR icon
Kymera Therapeutics
KYMR
+$25.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.93%
2 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZNTL icon
76
Zentalis Pharmaceuticals
ZNTL
$329M
– –
-200,000
Closed -$10.6M
KLRS
77
Kalaris Therapeutics
KLRS
$79.5M
– –
-19,435
Closed -$8.82M
SYRS
78
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-100,000
Closed -$5.45M
NGM
79
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-143,567
Closed -$3.16M
BCEL
80
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-2,426,685
Closed -$20.7M
KDNY
81
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-931,650
Closed -$13.2M
FSTX
82
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-46,000
Closed -$395K
TBIO
83
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-1,048,976
Closed -$28.9M
1 2 3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2021 Portfolio in Review

As of Q3 2021, EcoR1 Capital held 83 positions worth $2.87B, up 7.4% from $2.68B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital's Q3 2021 filing shows 11 new, 14 increased, 8 reduced and 12 closed positions. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 1,558,749 shares worth $82M. The largest sale was Relay Therapeutics, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Financials.

  • EcoR1 Capital's largest Q3 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 1,558,749 shares worth $82M.
  • EcoR1 Capital added most to Arcus Biosciences in Q3 2021, an estimated $55.6M increase.
  • EcoR1 Capital's biggest Q3 2021 reduction was Relay Therapeutics, cutting an estimated $104M.
  • EcoR1 Capital fully exited Translate Bio, Inc. Common Stock in Q3 2021, selling an estimated $28.9M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $2.87B portfolio in Q3 2021.
  • EcoR1 Capital opened 11 new positions and closed 12 in Q3 2021.
  • EcoR1 Capital's portfolio value rose 7.4% quarter-over-quarter to $2.87B.

Based on EcoR1 Capital's 13F filing for Q3 2021, filed 15 Nov 2021.